Diarrhea, HIV, Malaria, Opportunistic Infections, Pneumonia
Conditions
Keywords
HIV, malaria, E. Coli, S. pneumoniae, drug resistance, antifolate, opportunistic infections, Africa, Kenya, East Africa
Brief summary
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) \[CTX\] prophylaxis. Because of the demonstrated beneficial effect, high tolerability and low cost of CTX, the United Nations Programme on HIV/AIDS (UNAIDS) recommends that HIV-infected persons with symptomatic HIV or depressed CD4 counts receive daily CTX. The effect of this recommendation on subsequent development of antimicrobial resistance to antifolates among important pathogens needs to be evaluated. The investigators measured the change in the prevalence of markers of antifolate resistance among P. falciparum, and the change in the prevalence of CTX resistance among S. pneumoniae, and E. coli in HIV-infected individuals receiving CTX daily prophylaxis. In addition, the investigators measured the change in the prevalence of naso-pharyngeal or oro-pharyngeal carriage of CTX resistant S. pneumoniae among children living in households where an HIV-infected adult was receiving CTX daily prophylaxis.
Detailed description
We conducted this study in Kisumu, Kenya where HIV prevalence is high and malaria is highly endemic. HIV infected and uninfected adults were assigned to receive daily CTX if CD4 cell count was \<350, or daily multivitamin if CD4 cell count was \>= 350 or if the client was HIV negative. All clients were then followed for a total of 6 months. At specified scheduled and sick visits, clients received a physical exam, blood smears, nasopharyngeal swabs and stool samples or rectal swabs. Samples collected at baseline and during follow-up were used to measure the change in CTX resistance among P. falciparum parasites, pneumococcus isolates, and commensal E. coli.
Interventions
DRUGCotrimoxazole (trimethoprim sulfamethoxazole)
Sponsors
Kenya Medical Research Institute
Centers for Disease Control and Prevention
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
ECT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Clients presenting to the CRC HIV counseling and testing site in Kisumu were eligible for the study if they met the following inclusion criteria: * 15 years of age or older * Able to make all follow-up visits (i.e. do not plan to leave Kisumu during the next 6 months, are not homebound) * Able to understand and give informed consent.
Exclusion criteria
Clients were not eligible for the study if they met any of the following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX | — |
| Change in nasopharyngeal pneumococcal resistance before and while taking daily CTX, and among children living in households where adults are taking daily CTX | — |
| Change in commensal E. coli resistance before and while taking daily CTX | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the effect of daily CTX prophylaxis on the etiology of diarrheal diseases in HIV-infected persons | — |
| To evaluate the serotype distribution of and immune response to colonizing pneumococci | — |
| To measure CTX-resistance among Salmonella and other enteric bacterial pathogens in patients with diarrhea in the study area | — |
| To measure the change in quality of life indicators among clients receiving daily CTX | — |
| To assess the cause of diarrheal diseases among HIV-infected persons | — |
| To assess the efficacy of sulfadoxine-pyrimethamine (SP) treatment of breakthrough P. falciparum parasitemia and clinical malaria among HIV-infected persons taking daily CTX prophylaxis | — |
| To measure sulfa metabolite levels in HIV-infected persons receiving daily CTX who develop a drug reaction, to determine if differing rates of metabolism contribute to the development of adverse reactions | — |
Countries
Kenya
Outcome results
None listed